Markets
Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) on April 27. The company’s shares closed last Wednesday at $68.77.
According to TipRanks.com, Souda is a 5-star analyst with an average return of 27.0% and a 73.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, AbCellera Biologics, and Twist Bioscience.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $88.67 average price target, a 26.3% upside from current levels. In a report issued on April 27, Canaccord Genuity also maintained a Buy rating on the stock with a $94.00 price target.